Delivered $616 million in total global revenue for 2025, driven by $594 million in U.S. BRIUMVI net sales, representing 92% year-over-year growth. Performance was characterized by consistent increases in new patient starts and a broadening prescriber base across both academic and community settings. Management attributes sustained momentum to physician confidence in long-term data, specifically 6-year extension results showing 90% of patients remained disability-progression free. The company achieve ...